2 Figure S1 . Evaluation of the consistency of the aldehyde latex beads. EVs extracted from the same glioma patient were mixed with different batches of aldehyde latex beads (Cat. 1743119 (A) and Cat. 1778357 (B)) at the same ratio (4 μg EVs /1μL beads). The captured EVs were labeled with anti-EGFR and the fluorescent secondary antibody. Flow cytometry analysis showed that the two batches of beads exhibited similar results on the expression of EGFR in the EVs.
3 Figure S2 . Optimization of the formula of the blocking buffer for flow cytometry analysis.
The blocking effect of different formulas of the blocking buffer (10 mM Glycine with 10% BSA, 100 mM Glycine with 10% BSA, 150 mM Glycine with 10% BSA, 100 mM Glycine with 5% BSA) was compared. 10% BSA in 100 mM or 150 mM glycine exhibited almost the same blocking effect that was much better than the one of 10 mM glycine, indicating that the glycine concentration of 100 mM is a relatively desired concentration with good blocking effect and without overblocking. 100 mM Glycine with 10% or 5% BSA exhibited almost the same blocking effect, indicating that 10% BSA would not cause overblocking.
This experiment was carried out using EVs from one glioma patient (4μg EVs:1 μL beads) and secondary antibody (anti-rat, ab150157, abcam, dilution 1/1000). Table S1 . Clinical information for patient profiling study. Tumor size are measured based on MRI and CT. Patients who did not undergo tumor resection have no pathology diagnosis. Table S2 . Information of patients enrolled in the study.
18 Table S3 . Fluorescent intensities of bead-bound EVs at different EV/bead ratio as measured by flow cytometry. 
